Provided by Tiger Trade Technology Pte. Ltd.

Moleculin Biotech

2.03
+0.06003.05%
Post-market: 2.080.0481+2.37%17:30 EDT
Volume:118.48K
Turnover:237.91K
Market Cap:10.01M
PE:-0.04
High:2.05
Open:2.00
Low:1.96
Close:1.97
52wk High:33.00
52wk Low:1.79
Shares:4.93M
Float Shares:4.89M
Volume Ratio:0.63
T/O Rate:2.42%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-55.8792
EPS(LYR):-158.0236
ROE:-503.80%
ROA:-69.18%
PB:-0.37
PE(LYR):-0.01

Loading ...

Moleculin Biotech Appeals Nasdaq Delisting Decision

TIPRANKS
·
Nov 22, 2025

Moleculin Biotech Faces Nasdaq Delisting After Equity Rule Violation

Reuters
·
Nov 22, 2025

Moleculin Biotech Reports Increased Loss Amid Ongoing Trials

TIPRANKS
·
Nov 14, 2025

Moleculin Biotech Nears First Unblinding Milestone in Pivotal Phase 3 AML Trial

Reuters
·
Nov 13, 2025

Moleculin Reports 60% of First 45 Subjects in Pivotal “Miracle” Phase 3 Aml Trial Consented

THOMSON REUTERS
·
Nov 13, 2025

Moleculin Biotech’s Strategic Advancements and Potential in Oncology: Buy Rating Justified by Key Partnerships and Promising Trials

TIPRANKS
·
Nov 13, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Floor & Decor, Starbucks, gold miners

Reuters
·
Nov 12, 2025

Moleculin Biotech Partners with UNC for Cancer Research

TIPRANKS
·
Nov 12, 2025

BUZZ-U.S. STOCKS ON THE MOVE-ExxonMobil, Yatra, Venture Global

Reuters
·
Nov 12, 2025

BUZZ-Moleculin rises after UNC partnership to study new pancreatic cancer treatment

Reuters
·
Nov 12, 2025

Moleculin Announces Grant Funded Research Evaluating Annamycin for the Treatment of Pancreatic Cancer at Unc-Chapel Hill

THOMSON REUTERS
·
Nov 12, 2025

Moleculin Biotech Releases New Corporate Presentation

TIPRANKS
·
Oct 31, 2025

Moleculin to Highlight Its Ongoing Phase 3 Acute Myeloid Leukemia “Miracle” Clinical Trial at the 14TH Annual Acute Leukemia Meeting

THOMSON REUTERS
·
Oct 30, 2025

Moleculin Biotech Secures Australian Patent for Annamycin, Expanding Global IP Portfolio

Reuters
·
Oct 29, 2025

Promising Developments in Moleculin Biotech’s Annamycin Drive Buy Rating

TIPRANKS
·
Oct 25, 2025

Moleculin Biotech’s Promising Drug Pipeline and Strategic Expansion Justify Buy Rating

TIPRANKS
·
Oct 23, 2025

Moleculin Biotech works with Atlantic Health on Phase 1B/2 study of Annamycin

TIPRANKS
·
Oct 23, 2025

Moleculin Biotech Launches Phase 1B/2 Trial of Annamycin for Advanced Pancreatic Cancer

Reuters
·
Oct 23, 2025

Moleculin Announces New Investigator-Initiated Study of Annamycin for Treating Pancreatic Cancer

THOMSON REUTERS
·
Oct 23, 2025

Moleculin Biotech Inc - Estimates Trial Cost at $1 Mln From 2026 to 2030

THOMSON REUTERS
·
Oct 23, 2025